

UPL

UPL Corporation Ltd, international arm of the UPL (United Phosphorus Ltd), has entered into an agreement to acquire Arystra Lifesciences for US\$4.2bn, making it to Top 5 in the world. UPL will now have sales of US\$5bn & 20%+EBDITA margins (pre synergies). Transaction provides UPL a perfect match with powerful synergies across geographies, crops and products, strengthened through best-in-class manufacturing & differentiated R&D capabilities. Acquisition is funded part by equity of US\$1.2bn & Debt of US\$3bn. It expects Net Debt/ EBDITA of 2.5-2.7x after accounting for synergies V/s 3.2-3.5x as of now. On EPS front, the transaction will add Rs10-12 in FY2020. The merger is expected to close in late CY2018 and early CY2019. We recommend a HOLD.

Expanded & diversified product portfolio: UPL boasts of an agrochemical product portfolio that is spread out across geographies and crops. The acquisition will not only boost UPL's product portfolio for crops where it already has a strong presence, but also in those where it has limited presence (e.g. wheat, barley, nuts and a wide variety of specialty crops). According to management, Arysta has a strong presence in bio solutions (among top eight global players) and seed treatment (ranked fourth globally).

Strengthened presence in Europe: The overseas revenue mix for UPL is tilted in favor LataM (33% of its sales) as of now; Europe contributes just 13% of its sales. However, post the acquisition of Arysta (for which Europe revenue contribution is at 39% and LataM is at 36% of sales), UPL will have a more balanced geographical revenue mix, with LataM accounting for 33-34% of sales & Europe's contribution rising to 24% of sales.

Cost synergies to improve: Arysta relies on contract manufacturers for raw material sourcing from low-cost manufacturing countries like India, China and Eastern Europe. The company also almost entirely sources its AIs from third-party manufacturers. Management has guided for cost synergies of US\$100-120mn in the first year of consolidation and US\$200mn annually thereafter.

Key Financials

Y/E March (₹ cr)	FY2017	FY2018	FY2019E	FY2020E
Net sales	16,312	17,378	19,811	38,656
% chg	16.1	6.5	14.0	71.2
Adj. Net profit	1,800	2,086	2,221	2,637
% chg	71.3	15.9	6.5	18.7
EBITDA margin (%)	17.8	19.8	18.8	19.7
EPS (₹)	35.5	41.1	43.8	52.0
P/E (x)	17.8	15.4	14.5	12.2
P/BV (x)	4.3	3.5	2.9	2.5
RoE (%)	27.1	25.2	22.1	20.1
RoCE (%)	19.1	19.8	20.3	19.0
EV/Sales (x)	1.9	1.8	1.5	1.4
EV/EBITDA (x)	10.8	9.0	8.2	6.9

Source: Company, Angel Research Note: CMP as of June 24, 2018, FY20 represents a merged no's

HOLD

CMP	₹633
Target Price	₹680
Investment Period	12 Months

Stock Info

Sector	Agrichemicals
Market Cap (₹ cr)	32,112
Net Debt (₹ cr)	2,579
Beta	1.4
52 Week High / Low	902/534
Avg. Daily Volume	54,588
Face Value (₹)	1
BSE Sensex	36,719
Nifty	11,085
Reuters Code	UPLL.BO
Bloomberg Code	UPLL.IN

Shareholding Pattern (%)

Promoters	27.7
MF / Banks / Indian FIs	13.8
FII / NRIs / OCBs	50.1
Indian Public / Others	8.4

Abs.(%)	3m	1yr	3yr
Sensex	6.6	13.9	40.4
UPL	(16.3)	(27.1)	97.9

3-year price chart



Source: Company, Angel Research

Sarabjit Kour Nangra

022-39357800 Ext: 6806

sarabjit@angelbroking.com

Outlook & Valuations: While the acquisition of Arysta would drive significant benefits, it would also result in a highly leveraged balance sheet for UPL. FY2020 net D/E would jump from 0.1 to 1.9x and FY2020 net debt to EBITDA would rise from 0.4 to 3.3x. Thus, the ROE and ROCE of the company will come down to 22.1% & 20.3% to 20.1% & 19.0% respectively. In addition, the EPS has come down from Rs54.1 to Rs52.0 for FY2020E, on back of the acquisition because of the interest and depreciation expenses increasing more than the synergy benefits, especially during first year of acquisitions. We, we believe that the stock will given the financials, will trade lower multiples. **Thus, we recommend a hold with a price target of Rs680.**

Research Team Tel: 022 - 39357800

E-mail: research@angelbroking.com

Website: www.angelbroking.com

DISCLAIMER

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment.

Angel Broking Pvt. Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within.

Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Pvt. Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Pvt. Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Pvt. Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly.

Angel Broking Pvt. Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.

Neither Angel Broking Pvt. Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information.

Note: Please refer to the important 'Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Pvt. Limited and its affiliates may have investment positions in the stocks recommended in this report.

Disclosure of Interest Statement	Aurobindo Pharmaceuticals
1. Analyst ownership of the stock	No
2. Angel and its Group companies ownership of the stock	No
3. Angel and its Group companies' Directors ownership of the stock	No
4. Broking relationship with company covered	No

Note: We have not considered any Exposure below ₹ 1 lakh for Angel, its Group companies and Directors

Ratings (Returns):	Buy (> 15%) Reduce (-5% to -15%)	Accumulate (5% to 15%) Sell (< -15%)	Neutral (-5 to 5%)
---------------------------	-------------------------------------	-----------------------------------------	--------------------